Akums Drugs and Pharmaceuticals IPO
Akums Drugs and Pharmaceuticals IPO is listed on BSE and NSE, priced at ₹646–₹679 per share. The stock debuted at ₹725, delivering a listing gain of 6.8%. The IPO had a lot size of ₹22 shares and a minimum investment of ₹14,938.
Akums Drugs and Pharmaceuticals Limited IPO
- IPO Dates
- Jul 30, 2024 – Aug 1, 2024
- Price band
- ₹646-679 per equity share
- Minimum Investment
- ₹14,938
- Issue size
- ₹1856.74 Cr
- Lot size
- 22
- Allotment Date
- Aug 2, 2024
- Listing
- Aug 6, 2024
- Listing At
- BSE, NSE
IPO timeline
-
Jul 30, 2024
Open Date
Completed
-
Aug 1, 2024
Close Date
Completed
-
Aug 2, 2024
Allotment Date
Completed
-
Aug 6, 2024
Listing Date
Completed
Price Summary
- Last closing
- 531.75 (-21.69%)
- 52 week high
- 622.95
- 52 week low
- 409.30
- Last update
Akums Drugs and Pharmaceuticals IPO Essentials
Akums Drugs and Pharmaceuticals IPO Details
Akums Drugs and Pharmaceuticals IPO is priced at ₹646-679 per share with a total issue size of 1856.74 crore. The IPO has a lot size of 22 shares and is listed on BSE and NSE.
- Issue price
- ₹646-679 per equity share
- Lot size
- 22 shares
- Face value
- ₹2 Per Equity Share
- Issue size
- Total ₹1,856.74 Cr :
#Fresh Issue : 10,014,727 shares(aggregating up to ₹680.00 Cr) +
#OFS : 17,330,435 shares of ₹2(aggregating up to ₹1,262.83 Cr) - Total issue size
- 2,73,45,162 shares
(aggregating up to ₹1856.74 crore) - Fresh issue
- 1,00,14,727 shares
(aggregating up to ₹680 crore) - Offer for sale (OFS)
- 1,73,30,435 shares
(aggregating up to ₹1176.74 crore) - Listing at
- BSE, NSE
- List price
- 725.0(NSE)
- Listing date
- Registrar
- Link Intime India Private Ltd
- Lead manager
-
ICICI Securities Limited, Axis Bank Limited, Citigroup Global Markets India Private Limited, Ambit Private Limited
Market Lot Size
Investors can bid for a minimum of 22 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 22 | ₹14,938 |
| Retail(max) | 13 | 286 | ₹1,94,194 |
Akums Drugs and Pharmaceuticals IPO Reservation
Akums Drugs and Pharmaceuticals IPO reservation details show category-wise allocation of shares. Out of the total 27,368,151 shares, approximately 29.73% are reserved for QIB, 14.87% for NII, 9.91% for retail investors, 0.89% for employees, and 44.6% for anchor investors.
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | 12,205,912 (44.6%) | |
| QIB Shares Offered | 8,137,276 (29.73%) | |
| NII (HNI) Shares Offered | 4,068,637 (14.87%) | |
| bHNI > ₹10L | 2,712,425 (9.91%) | 8,806 |
| sHNI < ₹10L | 1,356,212 (4.96%) | 4,403 |
| Retail Shares Offered | 2,712,424 (9.91%) | 123,292 |
| Employee Shares Offered | 243,902 (0.89%) | |
| Total Shares Offered | 27,368,151 (100%) |
Akums Drugs and Pharmaceuticals IPO Analytics
Akums Drugs and Pharmaceuticals IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Akums Drugs and Pharmaceuticals IPO Subscription Status
Akums Drugs and Pharmaceuticals IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
bHNI
sHNI
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 8,137,276 |
4,068,637
2,712,425
1,356,212
|
2,712,424 | 15,162,239 |
|
Day 1
30-07-24 05:00 PM
|
0.43 x |
1.96x
2.04x
1.80x
|
3.35 x | 1.37 x |
|
Day 2
31-07-24 05:00 PM
|
0.96 x |
8.48x
8.87x
7.70x
|
8.98 x | 4.43 x |
|
Day 3
01-08-24 05:00 PM
|
90.09 x |
42.10x
47.43x
31.45x
|
20.80 x | 63.44 x |
|
Total No. of Applications
|
bHNI | sHNI | Retail |
|---|---|---|---|
| 23,44,029 (Approx) | —x | —x | 17.07x |
Akums Drugs and Pharmaceuticals Valuations
Returns
- ROE
- 0.11%
- ROCE
- 3.37%
- RoNW
- -0.57
- PAT Margin
- 0.02
Fundamentals
- Debt / Equity
- 0.69
- Price / Book
- 13.69
Akums Drugs and Pharmaceuticals Financials( In Crs.)
| 31-Mar-24 | 31-Mar-23 | 31-Mar-22 | |
|---|---|---|---|
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.50 | 717.19 | 621.98 |
| Reserves & Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
Akums Drugs and Pharmaceuticals Company & Offer Insights
About Akums Drugs and Pharmaceuticals
Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
The company primarily provides end-to-end solutions for product development and manufacturing as well as research and development (R&D) of formulations, preparation and submission of regulatory dossiers in the Indian and global markets and other testing services. The company is also engaged in the manufacture and sale of branded drugs and active pharmaceutical ingredients (APIs).
As a CDMO, the company manufactures a wide range of dosage forms including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections and gummy bears, to name a few.
The company has produced a total of 4,025 commercialized formulations in over 60 dosage forms. In the financial year 2023, the company manufactured formulations for 26 of the top 30 pharmaceutical companies in India in terms of revenue. For its CDMO business, the company operates 10 manufacturing units with a cumulative production capacity of 49.21 billion units annually (as of September 30, 2023).
The company plans to expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs and Pharmaceuticals had a total of 16,463 employees, including 7,211 full-time employees and 9,252 contract employees.
Akums Drugs and Pharmaceuticals Promoter(s)
Sanjeev Jain, Sandeep Jain, Akums Master Trust are the company's promoters of Akums Drugs and Pharmaceuticals.
Akums Drugs and Pharmaceuticals IPO Issue Objectives
- •
- Repayment/ prepayment of indebtedness of the company and its Subsidiaries
- •
- Funding incremental working capital requirements of the company
- •
- Pursuing inorganic growth initiatives through acquisitions
- •
- General corporate purposes.
Akums Drugs and Pharmaceuticals IPO - Anchor Investors
Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) that offers a wide range of pharmaceutical products and services in India and abroad. It was established in 2004.The company primarily operates in end-to-end solutions involving product development and manufacturing, alongside research and development (R&D) of formulation, preparation and submission of regulatory dossiers, in the Indian and global market, as well as other testing services. Furthermore, the group is involved in producing and selling branded drugs and API.
As a CDMO, the company manufactures a wide range of dosage forms, including tablets, capsules, liquid medicines, vials, ampoules, blow-filled closures, topical preparations, eye drops, dry powder injections, and gummy bears, to name a few.The company has manufactured more than 60 dosage forms of total 4,025 commercialized formulations. That year, the company formulated for 26 of the top 30 pharmaceutical companies in India in terms of revenue in the FY 2023. For its business of CDMO, the company operates 10 units with cumulative annual production capacity of 49.21 billion units as of 30 September 2023.The company will expand its production capacity with two additional production units for its CDMO business to be commissioned in FY 2025. Some of its production facilities have been accredited by various global regulatory bodies such as the European Good Manufacturing Practice (EU-GMP), the World Health Organization Good Manufacturing Practice (WHO-GMP) and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs and Pharmaceuticals had an aggregate number of 16,463 employees, with 7,211 regular employees, contract employees 9,252, respectively.
Akums Drugs and Pharmaceuticals IPO - Peers Comparison
| Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
|---|---|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | -0.28 | -0.28 | 49.59 | N/A | -0.57 | 13.69 | Consolidated |
| Divi's Laboratories | 60.27 | 60.27 | 511.21 | 74.99 | 11.79 | 7.24 | Consolidated |
| Suven Pharmaceuticals Limited | 11.8 | 11.8 | 80.56 | 69.54 | 14.64 | 10.19 | Consolidated |
| Gland Pharma Limited | 46.9 | 46.89 | 483.41 | 42.45 | 8.85 | 4.12 | Consolidated |
| Torrent Pharmaceuticals Ltd. | 48.94 | 48.94 | 202.57 | 60.2 | 24.15 | 14.54 | Consolidated |
| Alkem Laboratories Ltd | 150.19 | 150.19 | 862.46 | 34.18 | 17.41 | 5.95 | Consolidated |
| Eris Lifesciences Ltd | 28.82 | 28.79 | 190.12 | 34.95 | 15.16 | 5.29 | Consolidated |
| JB Chemicals | 35.66 | 34.85 | 188.37 | 51.38 | 18.9 | 9.51 | Consolidated |
| Mankind Pharma Limited | 47.75 | 47.68 | 233.73 | 44.65 | 20.43 | 8.8 | Consolidated |
| Innova Captab Limited | 18.66 | 18.66 | 145.2 | 29.91 | 11.35 | 3.84 | Consolidated |
Notes:
- The P/E Ratio has been computed based on the closing price of equity shares on July 19, 2024, divided by the Diluted EPS.
- Return on Net Worth (%) = Net profit after tax, as restated / Average shareholders' equity (including minority interest) as restated at year/period end.
- NAV is computed as the closing net worth (excluding minority interest) divided by the closing outstanding number of equity shares.
- Net worth means the aggregate value of the paid-up share capital of the Company and all reserves created out of profits and securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, miscellaneous expenditure not written off, as per the restated balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation as at year/ period end, as per Restated Financial Statement of Assets and Liabilities of the Company.
Akums Drugs and Pharmaceuticals IPO - Strengths and Risks
Akums Drugs and Pharmaceuticals IPO strengths and risks highlight key business factors, financial position, and market sentiment that may impact investor interest.
Strengths
Risks
Contact Information
Contact Details
Akums Drugs and Pharmaceuticals
+91 11 6904 1000
304, Mohan Place, LSC Saraswati Vihar, Delhi - 110 034
Registrar Contact Details
Frequently Asked Questions
Click any question to reveal the answer
Akums Drugs and Pharmaceuticals IPO is a book-built IPO worth ₹1856.74 crore. The price band is ₹646–₹679 per share. The IPO opens on Jul 30, 2024 and closes on Aug 1, 2024. It will be listed on BSE and NSE. Link Intime India Private Ltd is the registrar.
The price band of Akums Drugs and Pharmaceuticals IPO is ₹646 to ₹679 per share.
The lot size of Akums Drugs and Pharmaceuticals IPO is 22 shares.
The minimum investment for Akums Drugs and Pharmaceuticals IPO is approximately ₹14,938 based on the upper price band .
Akums Drugs and Pharmaceuticals IPO opens on Jul 30, 2024 and closes on Aug 1, 2024.
The allotment date of Akums Drugs and Pharmaceuticals IPO is Aug 2, 2024.
Akums Drugs and Pharmaceuticals IPO is expected to be listed on Aug 6, 2024, on BSE and NSE .
Akums Drugs and Pharmaceuticals IPO listed on Aug 6, 2024. It was issued at ₹725.0(NSE) and is currently around ₹531.75 as on 14-May-2026 3:30 PM, which is approximately -21.7% versus issue price. The 52-week high is ₹622.95.
Based on listing and post-listing performance, Akums Drugs and Pharmaceuticals IPO delivered around -21.7% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Akums Drugs and Pharmaceuticals IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Akums Drugs and Pharmaceuticals IPO valuation snapshot: P/E N/A, EPS ₹/-, P/B 13.69, RoNW -0.57, and market cap N/A.
To apply for Akums Drugs and Pharmaceuticals IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Akums Drugs and Pharmaceuticals IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Akums Drugs and Pharmaceuticals IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Akums Drugs and Pharmaceuticals IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Akums Drugs and Pharmaceuticals IPO allotment status on IPO Ji for quick and easy access.